A systematic review of the quality of statistical methods employed for analysing quality of life data in cancer randomised controlled trials

被引:29
作者
Hamel, Jean-Francois [1 ]
Saulnier, Patrick [1 ]
Pe, Madeline [2 ]
Zikos, Efstathios [2 ]
Musoro, Jammbe [2 ]
Coens, Corneel [2 ]
Bottomley, Andrew [2 ]
机构
[1] Angers Univ Hosp, Dept Methodol & Biostat, 4 Rue Larrey, F-49100 Angers, France
[2] EORTC Headquarters, Qual Life Dept, Ave E Mounier 83, B-1200 Brussels, Belgium
关键词
Systematic review; Quality of life; Statistical methods; CELL-LUNG-CANCER; PROPHYLACTIC CRANIAL IRRADIATION; PHASE-III TRIAL; ETOPOSIDE CYCLOPHOSPHAMIDE METHOTREXATE; PATIENT-REPORTED OUTCOMES; PLACEBO-CONTROLLED TRIAL; DAILY DIARY CARD; RADIATION-THERAPY; CLINICAL-TRIALS; ORAL ETOPOSIDE;
D O I
10.1016/j.ejca.2017.06.025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: Over the last decades, Health-related Quality of Life (HRQoL) end-points have become an important outcome of the randomised controlled trials (RCTs). HRQoL methodology in RCTs has improved following international consensus recommendations. However, no international recommendations exist concerning the statistical analysis of such data. The aim of our study was to identify and characterise the quality of the statistical methods commonly used for analysing HRQoL data in cancer RCTs. Methods: Building on our recently published systematic review, we analysed a total of 33 published RCTs studying the HRQoL methods reported in RCTs since 1991. We focussed on the ability of the methods to deal with the three major problems commonly encountered when analysing HRQoL data: their multidimensional and longitudinal structure and the commonly high rate of missing data. Results: All studies reported HRQoL being assessed repeatedly over time for a period ranging from 2 to 36 months. Missing data were common, with compliance rates ranging from 45% to 90%. From the 33 studies considered, 12 different statisticalmethods were identified. Twenty-nine studies analysed each of the questionnaire sub-dimensions without type I error adjustment. Thirteen studies repeated the HRQoL analysis at each assessment time again without type I error adjustment. Only 8 studies used methods suitable for repeated measurements. Conclusion: Our findings show a lack of consistency in statistical methods for analysing HRQoL data. Problems related to multiple comparisons were rarely considered leading to a high risk of false positive results. It is therefore critical that international recommendations for improving such statistical practices are developed. (C) 2017 Published by Elsevier Ltd.
引用
收藏
页码:166 / 176
页数:11
相关论文
共 65 条
[1]   QUALITY-OF-LIFE IN PATIENTS WITH LIMITED SMALL-CELL CARCINOMA OF THE LUNG RECEIVING CHEMOTHERAPY WITH OR WITHOUT RADIATION-THERAPY, FOR CANCER AND LEUKEMIA GROUP-B [J].
AHLES, TA ;
SILBERFARB, PM ;
RUNDLE, AC ;
HOLLAND, JC ;
KORNBLITH, AB ;
CANELLOS, GP ;
GREEN, MR ;
PERRY, MC .
PSYCHOTHERAPY AND PSYCHOSOMATICS, 1994, 62 (3-4) :193-199
[2]   A RANDOMIZED STUDY OF BOLUS VS CONTINUOUS PUMP INFUSION OF IFOSFAMIDE AND DOXORUBICIN WITH ORAL ETOPOSIDE FOR SMALL-CELL LUNG-CANCER [J].
ANDERSON, H ;
HOPWOOD, P ;
PRENDIVILLE, J ;
RADFORD, JA ;
THATCHER, N ;
ASHCROFT, L .
BRITISH JOURNAL OF CANCER, 1993, 67 (06) :1385-1390
[3]  
[Anonymous], 1996, J Clin Oncol, V14, P671
[4]  
[Anonymous], 2013, QUALITY LIFE ASSESSM
[5]  
Arnold AM, 2007, J CLIN ONCOL, V25, P4278, DOI 10.1200/JCO.2007.12.3083
[6]   Simultaneous and selective inference: Current successes and future challenges [J].
Benjamini, Yoav .
BIOMETRICAL JOURNAL, 2010, 52 (06) :708-721
[7]   Initial prognostic factors in small-cell lung cancer patients predicting quality of life during chemotherapy [J].
Bernhard, J ;
Hurny, C ;
Bacchi, M ;
Joss, RA ;
Cavalli, F ;
Senn, HJ ;
Leyvraz, S ;
Stahel, R ;
Ludwig, C ;
Alberto, P .
BRITISH JOURNAL OF CANCER, 1996, 74 (10) :1660-1667
[8]  
BLEEHEN NM, 1989, BRIT J CANCER, V59, P584
[9]   A RANDOMIZED TRIAL OF 3 OR 6 COURSES OF ETOPOSIDE CYCLOPHOSPHAMIDE METHOTREXATE AND VINCRISTINE OR 6 COURSES OF ETOPOSIDE AND IFOSFAMIDE IN SMALL-CELL LUNG-CANCER (SCLC) .1. SURVIVAL AND PROGNOSTIC FACTORS [J].
BLEEHEN, NM ;
GIRLING, DJ ;
MACHIN, D ;
STEPHENS, RJ ;
BARLEY, VL ;
BULLIMORE, JA ;
WHITE, RJ ;
BLEEHAN, NM ;
WILLIAMS, MV ;
BREDIN, CP ;
DAVIDSON, AR ;
WILLIAMS, TJ ;
ASH, DV ;
CLOSE, HJ ;
JOSLIN, CA ;
MUERS, MF ;
STONE, J ;
ASHFORD, RF ;
DISCHE, S ;
DUNPHY, EP ;
FERMONT, DC ;
GROSCH, E ;
MAHER, EJ ;
SAUNDERS, MI ;
ADAM, RJ ;
ALCOCK, CJ ;
BENSON, MK ;
HOPKIN, JM ;
LANE, DJ ;
HUNTER, AM .
BRITISH JOURNAL OF CANCER, 1993, 68 (06) :1150-1156
[10]  
BLEEHEN NM, 1993, BRIT J CANCER, V68, P1157, DOI 10.1038/bjc.1993.497